QUELL THERAPEUTICS LIMITED
Get an alert when QUELL THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-05-12
Overdue
Watchouts
Cash
£60M
-43.3% vs 2023
Net assets
£79M
+1% vs 2023
Employees
146
+5.8% vs 2023
Profit before tax
-£5M
+86.8% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Confirmation statement overdue
Due 2026-05-12.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £9,159,923 | £43,826,699 | |
| Operating profit | -£40,019,645 | -£8,109,055 | |
| Profit before tax | -£37,259,282 | -£4,936,564 | |
| Net profit | -£33,269,738 | -£2,505,629 | |
| Cash | £106,723,692 | £60,473,632 | |
| Total assets less current liabilities | £100,336,259 | £78,623,604 | |
| Net assets | £77,814,077 | £78,585,429 | |
| Equity | £77,814,077 | £78,585,429 | |
| Average employees | 138 | 146 | |
| Wages | £9,248,824 | £9,055,424 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -436.9% | -18.5% | |
| Net margin | -363.2% | -5.7% | |
| Return on capital employed | -39.9% | -10.3% | |
| Current ratio | 5.25x | 7.11x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ('the going concern period').”
Significant events
- “During 2024 the milestone for Tranche 3 of the company's Series B investment was met and funding of $18.8m was drawn down in February 2025.”
- “On 2 June 2023, the Company completed a research partnership agreement with AstraZeneca providing additional equity of £25m and income of £48m which will provide funds to support research programmes.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
9 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BESHAR, Luke Matthew | Director | 2024-07-24 | May 1958 | American |
| BINGHAM, Catherine Elizabeth, Dame | Director | 2023-07-28 | Oct 1965 | British |
| CLANCY, Annette | Director | 2025-06-13 | Nov 1954 | British |
| LECHLER, Robert, Sir | Director | 2020-06-02 | Dec 1951 | British |
| LONG-MCGIE, Jeffrey Stephen | Director | 2021-11-24 | Feb 1976 | American |
| MCGILL, Iain | Director | 2020-01-01 | May 1972 | British |
| PATEL, Dhavalkumar D, Dr | Director | 2020-06-02 | Aug 1961 | American |
| PETRIS, Elisa Michela, Dr | Director | 2019-03-19 | Jan 1979 | Italian,Canadian |
| RIVERS, Tyrell Jermaine | Director | 2023-06-02 | Nov 1972 | American |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MITRE SECRETARIES LIMITED | Corporate Secretary | 2019-03-19 | 2024-03-08 |
| ASHRAFIAN, Houman, Professor | Director | 2021-11-24 | 2023-08-15 |
| FUEYO, Alberto Sanchez, Professor | Director | 2019-03-29 | 2021-11-24 |
| MEARS, Rachel Brooke | Director | 2021-11-24 | 2025-05-31 |
| MURPHY, Martin Patrick, Dr | Director | 2019-03-19 | 2023-12-31 |
| RHIND, Stephen Keith | Director | 2019-03-29 | 2021-02-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Syncona Portfolio Limited | Corporate entity | Shares 50–75%, Voting 50–75% | 2019-03-29 | Ceased 2019-03-29 |
| Syncona Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2019-03-29 | Active |
Filing timeline
Last 20 of 84 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-11 | CH01 | officers | Change person director company with change date | |
| 2026-05-11 | CH01 | officers | Change person director company with change date | |
| 2026-04-21 | SH01 | capital | Capital allotment shares | |
| 2025-12-15 | SH06 | capital | Capital cancellation shares | |
| 2025-12-15 | SH03 | capital | Capital return purchase own shares | |
| 2025-12-15 | SH03 | capital | Capital return purchase own shares | |
| 2025-11-19 | SH06 | capital | Capital cancellation shares | |
| 2025-10-01 | SH08 | capital | Capital name of class of shares | |
| 2025-09-30 | SH10 | capital | Capital variation of rights attached to shares | |
| 2025-09-01 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-08-29 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-23 | AA | accounts | Accounts with accounts type full | |
| 2025-06-27 | AP01 | officers | Appoint person director company with name date | |
| 2025-06-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-06-06 | SH01 | capital | Capital allotment shares | |
| 2025-06-02 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-12 | AA | accounts | Accounts with accounts type full | |
| 2024-05-16 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-05-16 | CH01 | officers | Change person director company with change date | |
| 2024-05-14 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 16
- Capital events
- 8
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+378.5%
£9,159,923 £43,826,699
-
Cash
-43.3%
£106,723,692 £60,473,632
-
Net assets
+1%
£77,814,077 £78,585,429
-
Employees
+5.8%
138 146
-
Operating profit
+79.7%
-£40,019,645 -£8,109,055
-
Profit before tax
+86.8%
-£37,259,282 -£4,936,564
-
Wages
-2.1%
£9,248,824 £9,055,424
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers